MERCK KGAA
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1668-01-01
- Employees
- 62.9K
- Market Cap
- $84.2B
- Website
- http://www.merckgroup.com/de
Evaluation of Convenience and Compliance of the Easypod™ Electronic Self-injector
- First Posted Date
- 2008-08-20
- Last Posted Date
- 2014-03-11
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 834
- Registration Number
- NCT00738205
Cilengitide in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-06-25
- Last Posted Date
- 2014-04-30
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 184
- Registration Number
- NCT00705016
- Locations
- 🇨🇭
Research Site, Geneva, Switzerland
Long Term Follow up Study of Predictive Markers in GHD and TS Children
Completed
- Conditions
- First Posted Date
- 2008-06-18
- Last Posted Date
- 2014-02-19
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 182
- Registration Number
- NCT00699855
ChangE From Any Systemic psoriasiS therapY to Raptiva
Phase 4
Terminated
- Conditions
- Interventions
- First Posted Date
- 2008-06-16
- Last Posted Date
- 2014-02-13
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 70
- Registration Number
- NCT00697593
- Locations
- 🇨🇦
Probity Medical Research, City Waterloo, Ontario, Canada
Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-05-15
- Last Posted Date
- 2014-07-21
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 904
- Registration Number
- NCT00678535
- Locations
- 🇬🇧
Research site, Manchester, United Kingdom
🇨🇳Research Site, Taipei, Taiwan
Atacicept in Combination With Rituximab in Subjects With Rheumatoid Arthritis (August III)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-04-23
- Last Posted Date
- 2016-12-30
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 27
- Registration Number
- NCT00664521
- Locations
- 🇬🇧
Research Site, Norwich, United Kingdom
Transition to Rebif New Formulation
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-02-20
- Last Posted Date
- 2014-02-27
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 117
- Registration Number
- NCT00619307
- Locations
- 🇩🇪
Local Medical Information, Munich, Germany
AS900672-Enriched in Ovulation Induction
- First Posted Date
- 2007-11-04
- Last Posted Date
- 2014-02-13
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 71
- Registration Number
- NCT00553514
- Locations
- 🇨🇭
Merck Serono S.A., Geneva, Switzerland
Investigation of a Long-Acting Follicle Stimulating Hormone in Infertile Women Undergoing Assisted Reproductive Technology (ART)
- First Posted Date
- 2007-07-23
- Last Posted Date
- 2014-02-13
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 520
- Registration Number
- NCT00505752
- Locations
- 🇺🇸
Local US Medical Information Office, Rockland, Massachusetts, United States
r-hLIF for Improving Embryo Implantation in IVF
Phase 1
Completed
- Conditions
- First Posted Date
- 2007-07-20
- Last Posted Date
- 2017-01-04
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 50
- Registration Number
- NCT00504530
© Copyright 2024. All Rights Reserved by MedPath